重组人血管内皮抑制素联合顺铂抗血管形成作用的实验研究  

Experimental study on antiangiogenic effects of endostar combined with cisplatin

作　　者：吴穷[1] 秦叔逵[2] 王杰军[1] 曲文书[3] 殷晓进[4] 陈亚利[4] 华海清[2] 文勇[4] 

机构地区：[1]第二军医大学附属长征医院肿瘤科,上海200433 [2]南京解放军八一医院全军肿瘤中心内科,210002 [3]南京东南大学临床医学院,210009 [4]江苏先声药物研究有限公司,210042

出　　处：《临床肿瘤学杂志》2008年第5期385-392,共8页Chinese Clinical Oncology

基　　金：南京军区“十一·五”医学科研重点课题(06Z21);“十一·五”军队中医药重大临床攻关项目(2006051005)

摘　　要：目的:揭示新型重组人血管内皮抑制素(恩度,YH-16)与顺铂(CDDP)联合使用的抗血管形成作用。方法:首先以细胞增殖抑制、克隆形成实验和细胞凋亡分析,考察YH-16联合CDDP对人脐静脉内皮细胞(HUVECs)、肝癌细胞系QGY-7701和SMMC-7721生物学活性的影响;其次,在HUVECs体外培养体系上,评价两药联合使用对细胞迁徙/侵袭和管道形成的抑制作用。结果:YH-16与CDDP联合使用能协同地抑制HUVECs增殖和克隆形成,并增强了诱导细胞凋亡,上述作用具有血管内皮细胞特异性。两药联合使用对HUVECs的迁徙/侵袭和管道形成也有协同的抑制作用。结论:在血管形成的多个环节上,YH-16与CDDP联合使用提高了抗血管形成的效能,联合用药模式具有临床推广价值。Objective：To reveal the antiangiogenic effects of novel recombinant human endostatin（endostar,YH-16）combined with cisplatin（CDDP）.Methods：Firstly,using the methods including proliferation inhibition assay,clonogenic assay and induction apoptosis,we investigated the biological activity of combined modality on HUVECs,QGY-7701 and SMMC-7721.Secondly,migration /invasion assay and tube formation study were used to evaluate the antiangiogenic efficacy of combined modality on the cultivated system of HUVECs in vitro.Results：When YH-16 was used with CDDP,there were synergistic antiproliferative and reduced clonogenic effects,meanwhile,the enhanced apoptosis exhibited,and these effects were specific on endothelial cells.The combined modality had the synergistic inhibitory effects of migration/invasion and tube formation functions of HUVECs.Conclusion：In the course of vascular evolution,YH-16 combined with CDDP improved the efficacy and potency of antiangiogenic therapeutic efficacy.This therapeutic modality is valuable for the cancer treatment in clinic.

关 键 词：重组人血管内皮抑制素 顺铂 人脐静脉内皮细胞 抗血管形成作用 

分 类 号：R730.51[医药卫生—肿瘤]